Literature DB >> 28065915

Effective orifice area and hemodynamic performance of the transcatheter Edwards Sapien 3 prosthesis: short-term and 1-year follow-up.

Mischa Külling1, Jeremy Külling2, Christophe Wyss3, David Hürlimann3, Ivano Reho3, Sacha Salzberg3, Ines Bühler3, Georg Noll3, Jürg Grünenfelder3, Roberto Corti3, Patric Biaggi3.   

Abstract

Aims: The Edwards Sapien 3 heart valve prosthesis (S3) is commonly used for transcatheter aortic valve implantation (TAVI) and is available in three sizes. To date no data has been published on the effective orifice area (EOA) and the hemodynamic performance of the three different S3 sizes. The aim of this study was to measure the size-specific EOA and hemodynamic performance of the S3 in short-term and 1-year follow-up. Methods and results: One hundred and thirteen consecutive patients treated by TAVI with a S3 prosthesis at the Heart Clinic Zurich between May 2014 and July 2015 were included. Clinical data were extracted from the Swiss TAVI registry. The EOA was calculated using Doppler echocardiography (peri-interventionally and at discharge) and by 3D-biplane transoesophageal echocardiography (peri-interventionally). Mean transvalvular gradients (dPmean) were additionally calculated with Doppler echocardiography at 30 days and 1 year. Results were analysed separately for the 23 mm (n = 42; 37%), 26 mm (n = 46; 41%), and 29 mm (n = 25; 22%) prostheses. At discharge, the EOAs were 1.6 ± 0.2 cm2 (23 mm S3), 2.0 ± 0.2 cm2 (26 mm S3), and 2.7 ± 0.2 cm2 (29 mm S3), p < 0.001. The dPmeans at discharge were 10.9 ± 6.0 mmHg (23 mm S3), 10.4 ± 3.5 mmHg (26 mm S3), and 8.9 ± 2.8 mmHg (29 mm S3), p = 0.235, and did not significantly change over time within any of the S3 sizes. Conclusions: Post-TAVI, the EOAs of the three different S3 prosthesis sizes differ significantly, the transvalvular gradients, however, are comparable. Mean transvalvular gradients remain stable over time and document good prosthesis function after 1 year. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2017. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Edwards Sapien 3; TAVI; effective orifice area; percutaneous aortic valve implantation; transvalvular gradient

Mesh:

Year:  2018        PMID: 28065915     DOI: 10.1093/ehjci/jew301

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  4 in total

1.  Hemodynamics of self-expanding versus balloon-expandable transcatheter heart valves in relation to native aortic annulus anatomy.

Authors:  Matti Adam; Victor Mauri; Sarah Schmidt; Vera Fortmeier; Sebastian Ludwig; Hendrik Wienemann; Maria Isabel Körber; Samuel Lee; Max Meertens; Sascha Macherey; Christos Iliadis; Elmar Kuhn; Kaveh Eghbalzadeh; Sabine Bleiziffer; Stephan Baldus; Niklas Schofer; Tanja Katharina Rudolph
Journal:  Clin Res Cardiol       Date:  2022-06-15       Impact factor: 5.460

2.  Effective Orifice Area of Balloon-Expandable and Self-Expandable Transcatheter Aortic Valve Prostheses: An Echo Doppler Comparative Study.

Authors:  Mohamad Kanso; Marion Kibler; Sebastien Hess; Jérome Rischner; Philoktimon Plastaras; Michel Kindo; Minh Hoang; Fabien De Poli; Pierre Leddet; Hélène Petit; Floriane Zeyons; Annie Trinh; Kensuke Matsushita; Olivier Morel; Patrick Ohlmann
Journal:  J Clin Med       Date:  2021-01-07       Impact factor: 4.241

3.  Early outcomes of transatrial mitral valve replacement in severe mitral annular calcification.

Authors:  Yuji Kawano; Paige Newell; Morgan Harloff; Sameer Hirji; Edward Percy; Pinak Shah; Tsuyoshi Kaneko
Journal:  JTCVS Tech       Date:  2021-06-17

4.  Direct Flow Medical vs. Edwards Sapien 3 Prosthesis: A Propensity Matched Comparison on Intermediate Safety and Mortality.

Authors:  Christoph Edlinger; Marwin Bannehr; Bernhard Wernly; Tanja Kücken; Maki Okamoto; Michael Lichtenauer; Valentin Hähnel; David Reiners; Michael Neuss; Christian Butter
Journal:  Front Cardiovasc Med       Date:  2021-06-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.